Related Experiment Videos
The diagnosis of diffuse axonal injury: implications for forensic practice
J F Geddes1, G H Vowles, T W Beer
1Department of Morbid Anatomy, Royal London Hospital, Whitechapel, UK.
Neuropathology and Applied Neurobiology
|August 1, 1997
Summary
Diagnosing diffuse axonal injury (DAI) requires extensive brain sampling. Limited brain tissue sampling is unreliable for detecting DAI, especially when using beta-amyloid precursor protein (beta APP) and PG-M1 immunocytochemistry.
Area of Science:
- Neuropathology
- Forensic Medicine
- Immunohistochemistry
Background:
- Diffuse axonal injury (DAI) diagnosis is crucial in forensic medicine.
- Widespread brain sampling is typically needed for histological diagnosis of DAI.
- A limited sampling method could benefit medico-legal work.
Purpose of the Study:
- To evaluate a limited brain sampling method for DAI diagnosis.
- To assess the reliability of three tissue blocks for DAI screening.
- To investigate the utility of beta-amyloid precursor protein (beta APP), CD68 (PG-M1), and GFAP in DAI diagnosis.
Main Methods:
- Studied 22 diagnosed DAI cases with varying survival times.
- Utilized immunohistochemistry for beta APP, CD68 (PG-M1), and GFAP.
- Applied strict histological criteria to assess traumatic damage and its evolution.
Main Results:
- The limited sampling scheme missed axonal damage in 4/22 cases.
- DAI diagnosis would have been missed in 9/22 cases with this limited sampling.
- Beta APP positivity in early cases showed both ischaemia and traumatic damage, complicating interpretation.
Conclusions:
- Restricted brain tissue sampling is insufficient for reliable DAI diagnosis.
- Beta APP and PG-M1 immunocytochemistry can present interpretative challenges in DAI.
- Accurate DAI diagnosis necessitates a larger series of histological tissue samples.